Health Condition 1: B354- Tinea corporis Health Condition 2: B356- Tinea cruris
Conditions
Interventions
Intervention1: Qurs-e-Asfar: Participants in the Study Group will receive Qurs-e-Asfar tablets - 01 tablet twice daily after food.
Intervention2: Marham-e- Dad: Marham-e-Dad cream, mixed with vinegar,
Sponsors
Central Council for Research in Unani Medicine
Eligibility
Inclusion criteria
Inclusion criteria: Participants of Quba Tinea Corporis (body) & Tinea Cruris (groin) having Circumscribed lesions having any of the following signs and Symptoms: Presence of pruritus and burning, Presence of scales, Presence of central clearing, Erythematous papules. Participants with positive mycology (KOH positive). Willingness to participate in the study and follow the schedule
Exclusion criteria
Exclusion criteria: Participants below 18 years or above 60 years of age, pregnant or lactating women, and those having other forms of tinea infection such as Tinea capitis (scalp), Tinea pedis (foot), Tinea manuum (hands), Tinea unguium (nails), Tinea barbae (beard), or Tinea faciei (face) will be excluded from the study. Patients suffering from psoriasis, eczema, diabetes mellitus, pulmonary, cardiovascular, hepatic, or renal dysfunction, or any immunocompromised condition such as HIV/AIDS will also be excluded. Participants unwilling to attend the treatment schedule regularly, those with a history of hypersensitivity to Itraconazole or Terbinafine, and those who have used systemic antifungal or corticosteroid therapy in the previous two weeks will not be included in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Topical and oral treatment with Unani formulations Qurs-e-Asfar and Marham-e-Dad is expected to resolve the clinical signs and symptoms of Quba (Dermatophytosis) and achieve mycological cure, evidenced by negative findings in KOH mount, with minimal side effects as compared to the control drugsTimepoint: 8 week | — |
Secondary
| Measure | Time frame |
|---|---|
| To evaluate changes in gene expression levels of CXCL8, CXCL1, and TSG6, and to measure serum protein biolevels of IL6, IL17, IL23, and TNF alfa in Quba infected patients before and after treatment, in order to understand their role in the therapeutic response and pathogenesis of the diseaseTimepoint: 8 week | — |
Countries
India
Contacts
Public ContactSyeda Hajra Fatima
National Research Institute of Unani medicine for Skin Disorders
Outcome results
None listed